|Slideshows|March 4, 2021

5 Types of Anxious Bipolar Disorder

In what 5 ways can anxiety present in bipolar disorder?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

ByJoseph F. Goldberg, MD,Robert M. Post, MD

June 5th 2026

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

ByMark Gerstein, PhD

June 5th 2026

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

ByLeah Kuntz

June 4th 2026

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

ByJessica Walters

May 29th 2026

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

ByMark Zimmerman, MD

May 27th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

5 Types of Anxious Bipolar Disorder

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Artificial Intelligence in Psychopharmacology: Promise and Pitfalls, With Roy Perlis, MD

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

Addressing Sexual Wellness: A Psychiatric Perspective

What Do Orexin-2 Receptor Agonists Mean for Psychiatry?